• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Novartis proposes to close U.K. site, 371 jobs may be cut

Novartis proposes to close U.K. site, 371 jobs may be cut

November 6, 2013
CenterWatch Staff

Novartis U.K. will initiate consultation on proposals to close its Horsham site in West Sussex, affecting up to 371 employees, but subject to an employee consultation process and final U.K. board approval.

Novartis said it understands that this will be a difficult time for potentially affected employees, their families and the wider Horsham community, given the links the company has in the area. Novartis will work closely with associates, contractors, suppliers and local stakeholder groups to make the process as straightforward and smooth as possible.

This potential restructure of operations at the Horsham site is the result of a global review of research operations and realignment of other global R&D sites. The proposals are part of the company's ongoing efforts to align resources to better serve patients and customers in a challenging healthcare marketplace.

Separately, the U.K. pharmaceuticals division based at Frimley, Surrey, will be announcing the proposed withdrawal of marketing and sales support for products in diabetes and chronic obstructive pulmonary disease (COPD) in the U.K. All these products will still be available to customers and patients in the U.K. with no change in supply or accessibility. This may affect 72 employees, mostly field based.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing